The World Diabetes Market 2006-2012 2017 2025 A Key Pharmaceutical Market of the Future

Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. You cannot afford to ignore this market. To ignore this report when your competitors are reading it, would be a mistake. I urge you to read this report today.

Do you know what the prevalence of diabetes will be in 2007 to 2025? Will the oral anti-diabetics drugs and insulins still dominate the diabetes market until 2012? Which regions will be the main sales generator contributing sales into diabetes market? In addition, do you know what the drivers and restraints of the market are? This report explains just how this market will experience growth over the medium term future. This report not only reveals this, but also examines the key player's strategies used to maximize profits and R&D as well as the relevant studies and trials. The new technologies for anti-diabetic treatment will be also illustrated in this report.

Analysis in the report looks at the 7 major markets, aswell as the leading 7 expanding markets:

7 Major markets

Japan

France

Germany

Italy

Spain

E7 (expanding markets)

China

India

Indonesia

Turkey

Mexico

Brazil

Russia

In the year 2000, the global retail sales of diabetes drugs was US$8.1 billion - the market has tripled in 6 years - Do you have as large a segment of that market as you want? What is the revenue for oral anti-diabetics compared to insulin - this report tells you.

In 2000 visiongain predicted that the retail market for diabetes medications would exceed US$20 billion annually by 2006 - we were right. If you want to know the shape and direction of the market in 2012 and 2025, you should order visiongain's Diabetes Market report now.

This report is arranged to provide you with in-depth analysis of the diabetes drug market accompanied by forecasts by product type, country and application. Information on the leading diabetes drugs for the treatment of type 1 and 2 diabetes as well as a brief look at the drugs for treating the complications associated with diabetes will be presented in this report.

Forecasts of the market and an analysis of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. The main areas of pharmaceutical developments within the diabetes market are delivery technologies for treatment of type 1 diabetes and drugs for the treatment of type 2 diabetes.

Market figures regarding the current value of the diabetes drug market is taken from the most recently available data of the global pharmaceutical industry.

Key Market for the Future

In this report the treatments of diabetes will be examined in terms of the classification of drugs, the current markets and sales forecasts for leading drugs as well as new block busters.

According to the findings of this new 164+ page report, visiongain reveals that oral anti-diabetic therapies are set to dominate the market over the forecast period (2007-2012); insulin therapies will also expand rapidly. Visiongain predicts that the diabetes market will continue to show significant growth for what is an already large market. New blockbusters: Januvia, Galvus, Byetta and Levemir will bring significant sales into diabetes market.

Actos and Lantus are existing leading products for oral anti-diabetic drugs and insulin. However, are there any others which can compete with this for market share or beat its dominance? This report answers that question with an analysis of other players in the market.

Why You Must Buy This Report?

> Diabetes treatment is a leading therapeutic area and is about to become even more important.

> The world's first DDP-IV inhibitor and GLP-1 inhibitors have just been approved to the world's leading pharmaceutical companies. This report will help you to assess just what impact that this is likely to have.

> The market is dominated by a Japanese product - will this situation be changed by new blockbusters?

> Who are the key players in diabetes market? What kind strategies do these companies use for their sales development and product lifecycle management? Are these strategies developed differently by different regions?

> Visiongain has taken the latest available financial and prevalence statistics with forecast revenue figures for main regions, all the leading products and blockbusters to 2012 and 2025.

> The report contains strategic analysis of the pipeline, and the current market and strategic analysis for key players.

This report features over 35 tables, 43 charts, news, insights, the latest developments and an in depth survey of the diabetes market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' over your competitors. You can not afford to be without this latest report from visiongain.

With an increasingly aged population and unmet medical needs this market is set to grow rapidly, but by how much? This report will tell you. Brought together into one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global diabetes pharmaceutical market.

Key questions that this report answers are:

* Which current or future therapies will drive the diabetes market?

* The key companies involved in the market and their analysis?

* What R&D opportunities and new drug delivery technologies exist for 'new comers'?

* What are the current and future blockbusters within the diabetes industry?

* What are the main drivers and key restraints of growth?

Put together with in-depth primary research and interviews, this report is not available anywhere else.

October 2007 PDF

- PRICING -

- Individual report pricing - single user copies of this report are available for only GBP£1499

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only GBP£2999. This is not suitable for library usage.

- Allow your whole company to have access to this information for only GBP£4999. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only GBP£6999

Table of Contents
Sample Pages

Price
Single User Licence $2995.00
Department Licence 5 Users $5995.00
Company-wide Intranet Licence $9995.00